Beyond treatment response: Injection‐site reactions as part of the extended‐release buprenorphine experience
Addiction · 2026-09 · 121 (9) · 2575-2576
DOI: 10.1111/add.70496 ↗At a glance
Leserbrief in Addiction, published online on 2026-05-30. Written by Julien Cabé and 1 co-authors. Institution: Department of Addictology and Dual Disorders, Clermont-Ferrand University Hospital, Clermont-Ferrand, France. 14 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
involve a mixture of distressing and beneficial bodily experiences [12]. In that context, proactive explanation of possible local reactions may reduce anxiety, improve preparedness and support adherence. Prevention should therefore be considered part of routine care: strict subcutaneous administration, correct angle and depth of injection, site rotation and avoidance of local friction after injection are all simple but important measures [13, 14]. Early conservative management of mild reactions with cold compresses and standard analgesics, and of more moderate reactions with topical hydrocortisone and oral antihistamines, may help support treatment acceptability and maintain patient confidence [11]. Some published reports further suggest applying ice for 10 – 15 minutes before injection to reduce pain, and considering local analgesia when pain is more substantial [11, 13, 14]. If long-acting injectable buprenorphine is to achieve its full potential, injection-site reactions should not be framed primarily as a barrier to treatment uptake. Rather, they should be understood as predictable and usually manageable events that require good technique, patient education and early clinical attention. A clearer and more standardized approach to anticipating and managing these reactions may help preserve adherence and strengthen confidence in a treatment with substantial clinical benefit.
Subjects
Author keywords
Authors and institutions
- Department of Addictology and Dual Disorders, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
- Clermont Auvergne University, Centre National de la Recherche Scientifique (CNRS), Clermont Auvergne Institut National Polytechnique (INP), Institut Pascal, Clermont-Ferrand, France.
ORCID profiles: Julien Cabé
Cite
APA
Cabé, J., & Brousse, G. (2026). Beyond treatment response: Injection‐site reactions as part of the extended‐release buprenorphine experience. Addiction, 121(9), 2575-2576. https://doi.org/10.1111/add.70496
Vancouver
Cabé J, Brousse G. Beyond treatment response: Injection‐site reactions as part of the extended‐release buprenorphine experience. Addiction. 2026;121(9):2575-2576. doi:10.1111/add.70496
BibTeX
@article{Cab2026,
author = {Cabé, Julien and Brousse, Georges},
title = {Beyond treatment response: Injection‐site reactions as part of the extended‐release buprenorphine experience},
journal = {Addiction},
year = {2026},
volume = {121},
number = {9},
pages = {2575--2576},
doi = {10.1111/add.70496}
}
EUVIMED